A Phase 2b, Open-Label, Long-Term Extension Study to Evaluate the Safety and Pharmacodynamics of KRN23 in Adult Subjects with X-Linked Hypophosphatemia (XLH)

Administered By

School of Medicine

Awarded By

Ultragenyx Pharmaceutical

Contributors

Weber, Thomas Joseph Principal Investigator

Start/End

March 15, 2015 - November 30, 2019